RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
PG
Playground Global
Activity from announced rounds
Activity in this selectionBiotech
Playground Global is a deep-technology firm whose official portfolio identifies Infinimmune and PicoJool and which Mesa names as financing lead.
Recorded funding activity
Mesa develops miniature quantum sensors. PicoJool develops optical computing links, while RegCell develops reprogrammed immune-cell therapies. These investments concern different physical and biological systems.
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $132.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionRegCell, Inc.
$44MSeries A
LeadInfinimmune
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
$75MSeries A
Role not disclosedUnreasonable Labs
Builds an AI reasoning engine to generate scientific hypotheses across chemistry, materials science, and biology for industrial R&D
$13.5MSeed
Role not disclosed